Stephen Gordon Biography and Net Worth

CFO of TransMedics Group

Stephen Gordon joined TransMedics in March of 2015 and leads our finance and accounting team. He has over 20 years of experience leading financial organizations within high technology and medical device companies. During this time his areas of focus have been strategic planning, M&A integration, financial planning and analysis, and improvement in the presentation of quantitative information. Prior to joining TransMedics, Mr. Gordon was the Vice President, Financial Planning & Analysis at Analogic Corporation, a medical device and security technology company. Before joining Analogic, Mr. Gordon held various financial leadership positions at Hologic, Cytyc, Maxtor and Hewlett-Packard. Mr. Gordon earned a Bachelor’s degree in Finance and Accounting from The Wharton School at The University of Pennsylvania, and an MBA from Boston University.

What is Stephen Gordon's net worth?: The estimated net worth of Stephen Gordon is at least $2.43 million as of June 3rd, 2024. Mr. Gordon owns 21,299 shares of TransMedics Group stock worth more than $2,428,086 as of April 11th. This net worth approximation does not reflect any other assets that Mr. Gordon may own. Learn More about Stephen Gordon's net worth.
How do I contact Stephen Gordon?: The corporate mailing address for Mr. Gordon and other TransMedics Group executives is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. TransMedics Group can also be reached via phone at (978) 552-0900 and via email at [email protected]. Learn More on Stephen Gordon's contact information.
Has Stephen Gordon been buying or selling shares of TransMedics Group?: Stephen Gordon has not been actively trading shares of TransMedics Group over the course of the past ninety days. Most recently, Stephen Gordon sold 2,060 shares of the business's stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $135.93, for a transaction totalling $280,015.80. Following the completion of the sale, the chief financial officer now directly owns 21,299 shares of the company's stock, valued at $2,895,173.07. Learn More on Stephen Gordon's trading history.
Who are TransMedics Group's active insiders?: TransMedics Group's insider roster includes John Carey (VP), Nicholas Corcoran (Insider), Laura Damme (VP), Stephen Gordon (CFO), Waleed Hassanein (CEO), Gerardo Hernandez (CFO), Edwin Kania, Jr. (Director), Tamer Khayal (Insider), Miriam Provost (VP), Anil Ranganath (Insider), and David Weill (Director). Learn More on TransMedics Group's active insiders.
Are insiders buying or selling shares of TransMedics Group?: In the last year, insiders at the sold shares 14 times. They sold a total of 41,685 shares worth more than $5,663,249.30. The most recent insider tranaction occured on March, 4th when CFO Gerardo Hernandez sold 7,236 shares worth more than $1,065,211.56. Insiders at TransMedics Group own 7.0% of the company. Learn More about insider trades at TransMedics Group.
Information on this page was last updated on 3/4/2026.

Stephen Gordon Insider Trading History at TransMedics Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/3/2024	Sell	2,060	$135.93	$280,015.80	21,299
5/29/2024	Sell	20,000	$141.40	$2,828,000.00	21,299
5/6/2024	Sell	15,000	$128.00	$1,920,000.00	23,299
4/1/2024	Sell	15,000	$74.01	$1,110,150.00	23,299
3/8/2024	Sell	1,903	$87.63	$166,759.89	23,299
3/4/2024	Sell	15,000	$82.80	$1,242,000.00	25,202
2/1/2024	Sell	15,000	$85.45	$1,281,750.00	13,075
1/2/2024	Sell	15,000	$77.07	$1,156,050.00	13,075
10/2/2023	Sell	5,000	$54.22	$271,100.00	18,789
5/1/2023	Sell	5,000	$79.05	$395,250.00	18,789
3/1/2023	Sell	5,000	$79.51	$397,550.00	18,789
1/17/2023	Sell	5,000	$60.12	$300,600.00	5,714
11/7/2022	Sell	10,000	$56.72	$567,200.00	5,714
10/3/2022	Sell	10,000	$41.74	$417,400.00	5,714
7/5/2022	Sell	10,000	$35.00	$350,000.00	5,714
9/7/2021	Sell	10,000	$35.00	$350,000.00	15,714
7/15/2021	Sell	10,000	$35.00	$350,000.00	15,714
6/17/2021	Sell	10,000	$30.00	$300,000.00	10,000
3/15/2021	Sell	10,000	$39.81	$398,100.00	10,000
2/16/2021	Sell	10,000	$31.33	$313,300.00	10,000
2/8/2021	Sell	10,000	$25.01	$250,100.00
1/4/2021	Sell	10,000	$20.00	$200,000.00
4/27/2020	Sell	9,900	$18.00	$178,200.00	18,571
4/22/2020	Sell	100	$18.00	$1,800.00	28,471

Stephen Gordon Buying and Selling Activity at TransMedics Group

TransMedics Group Company Overview

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Today's Range

Now: $114.00

$109.97

$115.00

50 Day Range

MA: $123.84

$94.31

$148.00

2 Week Range

Now: $114.00

$75.50

$156.00

Volume

820,963 shs

Average Volume

972,351 shs

Market Capitalization

$3.91 billion

P/E Ratio

23.27

Dividend Yield

N/A

Beta

2.09